While a vast majority of Americans believe they possess a comprehensive understanding of skin protection, recent data suggests an alarming disconnect between self-reported knowledge and the actual biological consequences of ultraviolet exposure. The American Academy of Dermatology’s annual survey
Ivan Kairatov is a distinguished figure in the biopharmaceutical sector, known for his deep technical insights into the next generation of targeted oncology. With a career spanning decades in research and development, he has navigated the complex shift from broad chemotherapy to the era of
As construction begins on the £30 million Sir Bobby Robson Institute at Freeman Hospital, the landscape of oncology research in Northern England is poised for a transformative shift. This new three-story facility represents more than just a physical expansion; it is a strategic hub designed to
The effectiveness of a human's internal defense system might rely more on the timing of their last meal than previously understood by modern clinical science. While scientific inquiry has traditionally focused on how chronic nutritional states, such as long-term obesity or persistent malnutrition,
The clinical landscape of oncology shifted dramatically with the birth of cellular engineering, yet the early excitement often masked a persistent struggle against the rapid exhaustion of the very tools designed to save lives. While Chimeric Antigen Receptor (CAR) T-cell therapy has achieved
The biopharmaceutical industry is witnessing a fundamental departure from passive pharmaceutical agents to complex, programmable biological machines that actively navigate the human body. This shift marks the rise of multifunctional Chimeric Antigen Receptor (CAR) T-cell therapy, a modality that
